MUC16 (CA125), variant 4 (region 13785-14507) CHO Cell Line

Catalog #
78848
$7,150 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Engineered CHO cell line stably expressing human C-terminus MUC16 (CA125) transcript variant 4, from amino acid 13785 to 14507 (NM_024690.2). This portion of MUC16 contains several of the extracellular SEA modules, the transmembrane domain, and the short cytoplasmic tail of the protein. Surface expression of MUC16 was confirmed by flow cytometry. This stable clonal cell line was selected based on its high level of MUC16 expression compared to the parental CHO-K1 cell line.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Product Info
Storage and Usage
Citations
Host Cell Line
CHO-K1 cells, Chinese Hamster Ovary, epithelial-like cells, adherent
Supplied As
Each vial contains 2 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Materials Required But Not Supplied

Media Required for Cell Culture

Name Ordering Information
Thaw Medium 3 BPS Bioscience #60186
Growth Medium 3J BPS Bioscience #79974
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

MUC16 (also known as Mucin16, Cell Surface Associated, and ovarian cancer marker CA125) is a protein of the mucin family. Mucins are high molecular weight, O-glycosylated proteins found on the apical surfaces of epithelia. MUC16 has been found in the cornea, the respiratory system, and the female reproductive system, where it plays a role in protecting epithelial cells from pathogen entry. MUC16 dysfunction has been associated with dry eye, cystic fibrosis and cancer, in particular ovarian cancer. MUC16 binds to mesothelin and may be involved in migration and metastasis of tumor cells. Currently MUC16 is used as biomarker for certain cancer types, in addition to being studied in the context of cell signaling. Due to its high expression in some tumors, it is investigated as a therapeutic target for antibody-based therapy as well as adaptive cell therapy.